Roflumilast (Figure 6), a potent, selective, and long-acting PDE4 inhibitor, was introduced in 2011 as an anti-inflammatory drug for the treatment of severe chronic obstructive pulmonary disease (COPD). The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.